Company Overview and News


Add GHDX
to your dashboard

Headline News

Reimbursement cuts on lab tests pressure US lab firm shares - Channel NewsAsia

2017-11-20 channelnewsasia
REUTERS: A federal agency on Friday rolled out deep cuts to reimbursement rates for some lab tests under Medicare, a move that could save the government as much as US$3 billion over five years, but hurt margins of U.S. laboratory companies. (34-1)

Reimbursement cuts on lab tests pressure US lab firm shares

2017-11-20 reuters
(Reuters) - A federal agency on Friday rolled out deep cuts to reimbursement rates for some lab tests under Medicare, a move that could save the government as much as $3 billion over five years, but hurt margins of U.S. laboratory companies. (34-1)

Genomic Health Cancer Diagnostic Tests Grow Amid Cost Woes

2017-11-17 zacks
On Nov 15, we issued an updated research report on Genomic Health Inc (GHDX - Free Report) , a global cancer research company with focus on advanced molecular diagnostics. (35-1)

Vermillion's (VRML) CEO Valerie Palmieri on Q3 2017 Results - Earnings Call Transcript

2017-11-12 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to the Third Quarter 2017 Vermillion Earnings Conference Call. My name is Catherine, I will be your coordinator for the call today. With me today are Valerie Palmieri, President and Chief Executive Officer; Dr. Marra Francis, Chief Medical Officer; and Eric Schoen, Senior Vice President of Finance and Chief Accounting Officer. This afternoon, they will discuss Vermillion's Q3 2017 performance. (5-0)

Genomic Health's (GHDX) CEO Kim Popovits on Q3 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Good afternoon. My name is Glenda, and I will be your conference operator today. At this time, I would like to welcome everybody to Genomic Health Third Quarter 2017 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded. (43-0)

Genomic Health, Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-10 seekingalpha
The following slide deck was published by Genomic Health, Inc. in conjunction with their 2017 Q3 earnings call. (4-0)

Veracyte's (VCYT) CEO Bonnie Anderson on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to Veracyte’s Third Quarter 2017 Financial Results Conference Call. [Operator Instructions] As a reminder, today’s conference call is being recorded. I’d now like to turn the conference over to Ms. Jackie Cossmon, Vice President of Investor Relations and Corporate Communications for Veracyte. Ms. Cossmon, you may begin. (11-0)

Epic Sciences Release: Liquid Biopsy Test Identifies Androgen Receptor Protein Expression In Circulating Tumor Cells In Women With Metastatic Breast Cancer

2017-10-13 devicespace
SAN DIEGO, Oct. 13, 2017 /PRNewswire/ -- Epic Sciences along with researchers at the MD Anderson Cancer Center (MDA) have recently published their findings on androgen receptor (AR) protein expression in circulating tumor cells (CTCs) in patients with metastatic breast cancer in PLOS One.  The publication, the most comprehensive today in characterizing the AR protein in CTCs of patients with breast cancer, identifies subclonal heterogeneity of AR protein. (4-0)

Liquid Biopsy Test Identifies Androgen Receptor Protein Expression in Circulating Tumor Cells in Women with Metastatic Breast Cancer

2017-10-13 prnewswire
SAN DIEGO, Oct. 13, 2017 /PRNewswire/ -- Epic Sciences along with researchers at the MD Anderson Cancer Center (MDA) have recently published their findings on androgen receptor (AR) protein expression in circulating tumor cells (CTCs) in patients with metastatic breast cancer in PLOS One.  The publication, the most comprehensive today in characterizing the AR protein in CTCs of patients with breast cancer, identifies subclonal heterogeneity of AR protein. (4-0)

Genomic Health's Cost Pressure Mounts, Cancer Tests Strong

2017-10-05 zacks
On Oct 4, we issued an updated research report on Genomic Health Inc (GHDX - Free Report) , a global cancer research company with focus on advanced molecular diagnostics. (9-0)

Liquid Biopsy Market by Cancer Type, Circulating Biomarkers, Product, End User - Global Forecast to 2022

2017-10-03 prnewswire
LONDON, Oct. 3, 2017 /PRNewswire/ -- "Global liquid biopsy market projected to grow at a CAGR of 23.4%" The global liquid biopsy market is estimated to grow at a CAGR of 23.4% from 2017 to 2022, to reach USD 2,047.9 million by 2022. Increasing prevalence of cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market. (20-1)

Global Clinical Laboratory, Cardiac, Molecular Diagnostics and Genomic Testing Services 2017

2017-10-03 prnewswire
The "Clinical Laboratory, Cardiac, Molecular Diagnostics and Genomic Testing Services. Strategies & Trends. Volume & Price Forecasts by Laboratory Department by Country. 2017 to 2022 - Global Version" report has been added to Research and Markets' offering. (87-1)

Global In-Vitro Diagnostic Testing Services Market, 2022

2017-10-02 prnewswire
The "In Vitro Diagnostic Testing Services including Cardiac, Molecular Diagnostic and Genomic. Strategies & Trends. Price & Volume Forecasts by Laboratory Department by Country. 2017 to 2022 - Global Version" report has been added to Research and Markets' offering. (87-1)

Genomic Health Targets European Cancer IVD Marketplace With Biocartis Deal

2017-09-18 prnewswire
ROCKVILLE, Md., Sept. 18, 2017 /PRNewswire/ -- At least one market research firm thinks that Genomic Health's deal with Biocartis may not only assist the company with reaching European markets past competitors, but also foster a trend in the IVD market. Genomic Health announced on September 13th that they have entered into an exclusive agreement under which they will develop an in vitro diagnostic version of Genomic Health's Oncotype DX breast cancer test on Biocartis' Idylla platform. (8-1)

Genomic Health Ties up With Biocartis, Boosts Oncotype DX

2017-09-14 zacks
Genomic Health, Inc. (GHDX - Free Report)  and Biocartis Group NV (BCART) signed an agreement to develop an in vitro diagnostic (IVD) version of the Oncotype DX Breast Recurrence Scoretest on Biocartis' proprietary Idylla platform. This can be performed locally by laboratory partners as well as hospitals globally. Biocartis is an innovative molecular diagnostics company providing next generation diagnostic solutions.

CUSIP: 37244C101